First Trust Advisors LP Has $34.27 Million Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

First Trust Advisors LP boosted its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 8.2% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 324,473 shares of the medical equipment provider's stock after purchasing an additional 24,671 shares during the quarter. First Trust Advisors LP owned 0.16% of Zimmer Biomet worth $34,274,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of ZBH. CKW Financial Group lifted its holdings in Zimmer Biomet by 11.7% during the fourth quarter. CKW Financial Group now owns 955 shares of the medical equipment provider's stock worth $101,000 after acquiring an additional 100 shares in the last quarter. Romano Brothers AND Company raised its holdings in Zimmer Biomet by 1.1% during the 4th quarter. Romano Brothers AND Company now owns 9,466 shares of the medical equipment provider's stock worth $1,000,000 after buying an additional 102 shares during the period. Dorsey & Whitney Trust CO LLC boosted its holdings in shares of Zimmer Biomet by 2.3% in the fourth quarter. Dorsey & Whitney Trust CO LLC now owns 4,594 shares of the medical equipment provider's stock valued at $485,000 after buying an additional 102 shares during the period. M&T Bank Corp increased its position in shares of Zimmer Biomet by 0.4% during the fourth quarter. M&T Bank Corp now owns 26,827 shares of the medical equipment provider's stock worth $2,834,000 after acquiring an additional 108 shares in the last quarter. Finally, Dakota Wealth Management increased its holdings in Zimmer Biomet by 1.3% during the 4th quarter. Dakota Wealth Management now owns 9,620 shares of the medical equipment provider's stock worth $1,016,000 after purchasing an additional 122 shares in the last quarter. Institutional investors own 88.89% of the company's stock.

Analysts Set New Price Targets

A number of research firms recently issued reports on ZBH. Barclays decreased their price objective on Zimmer Biomet from $118.00 to $112.00 and set an "underweight" rating for the company in a report on Monday, February 10th. Truist Financial restated a "hold" rating and set a $113.00 target price (down previously from $118.00) on shares of Zimmer Biomet in a report on Monday, February 10th. BTIG Research restated a "buy" rating on shares of Zimmer Biomet in a research note on Monday, April 14th. Stifel Nicolaus upped their target price on Zimmer Biomet from $130.00 to $138.00 and gave the stock a "buy" rating in a report on Thursday, January 23rd. Finally, Raymond James dropped their price objective on Zimmer Biomet from $126.00 to $119.00 and set an "outperform" rating on the stock in a research note on Friday, February 7th. Two research analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Hold" and an average target price of $124.15.

Insider Buying and Selling at Zimmer Biomet

In other news, SVP Lori Winkler sold 1,443 shares of the firm's stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total transaction of $150,649.20. Following the transaction, the senior vice president now directly owns 8,768 shares of the company's stock, valued at approximately $915,379.20. This trade represents a 14.13 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.70% of the company's stock.

Zimmer Biomet Stock Performance

Shares of Zimmer Biomet stock traded down $0.04 on Friday, hitting $101.46. The stock had a trading volume of 1,661,962 shares, compared to its average volume of 1,669,704. The stock has a market cap of $20.07 billion, a price-to-earnings ratio of 22.80, a price-to-earnings-growth ratio of 1.95 and a beta of 0.84. The business's 50 day moving average is $105.81 and its two-hundred day moving average is $106.59. The company has a quick ratio of 0.99, a current ratio of 1.91 and a debt-to-equity ratio of 0.43. Zimmer Biomet Holdings, Inc. has a twelve month low of $93.10 and a twelve month high of $123.96.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last issued its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, beating analysts' consensus estimates of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same period last year, the business posted $2.20 EPS. Analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be paid a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 0.95%. The ex-dividend date is Monday, March 31st. Zimmer Biomet's dividend payout ratio (DPR) is 21.57%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.